Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 9, 2026

Renoprotective Mechanisms of SGLT2 Inhibitors: Integrating Clinical and Experimental Evidence from Inflammation to Fibrosis.

View Full Paper
Ask AI
Bookmark
Share

Authors

SPShatrudhan PrajapatiSYShikha YadavHAHimanshu Arora

Discussion

Loading...

Member takes

Overview

Randomized trials demonstrate SGLT2 inhibitors reduce kidney disease progression in CKD, implying potential clinical applications.

Key Points

  • This review aims to synthesize clinical and mechanistic evidence on the renoprotective effects of SGLT2 inhibitors in chronic kidney disease.
  • Review of large randomized trials including CREDENCE, DAPA-CKD, and EMPA-KIDNEY.
  • Assessment of renal outcomes regarding SGLT2 inhibitors' effects on inflammation and fibrosis.
  • Integration of experimental evidence on renal mechanisms involving metabolic and immune modulation.
  • Canagliflozin reduced risk of end-stage kidney disease by 34% (HR 0.66; 95% CI 0.53-0.81).
  • Dapagliflozin lowered composite renal outcomes risk by 39% (HR 0.61; 95% CI 0.51-0.72).
  • Empagliflozin demonstrated a 28% reduction in kidney progression or cardiovascular death (HR 0.72; 95% CI 0.64-0.82).

Cite This Study

Prajapati et al. (2026) studied this question.

synapsesocial.com/papers/6a4f3b002b81a944af5750c8https://doi.org/10.2174/0127722708450967260627052738
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Nephroprotective Mechanisms of SGLT2i: Beyond the Glucose-Lowering Effect2025 · 6 citations
  2. 2RENOPROTECTIVE EFFECTS OF SGLT2 INHIBITORS IN CHRONIC KIDNEY DISEASE BEYOND GLYCEMIC CONTROL2026
  3. 3SGLT-2 inhibitors in Diabetic Kidney Disease: What Lies Behind their Renoprotective Properties?2018 · 6 citations
  4. 4THE EFFECTS OF SGLT2 INHIBITORS IN CARDIOVASCULAR PROTECTION: A REVIEW OF MECHANISTIC INSIGHTS AND CLINICAL EVIDENCE2026
  5. 5Potential mechanisms of sodium-glucose cotransporter 2 inhibitors in regulating cardiac and renal fibrosis2026